Irit Gliko-Kabir
Direttore Tecnico/Scientifico/R&S presso BIOLINERX LTD.
Posizioni attive di Irit Gliko-Kabir
Società | Posizione | Inizio | Fine |
---|---|---|---|
BIOLINERX LTD. | Direttore Tecnico/Scientifico/R&S | 01/09/2017 | - |
Storia della carriera di Irit Gliko-Kabir
Precedenti posizioni note di Irit Gliko-Kabir
Società | Posizione | Inizio | Fine |
---|---|---|---|
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Direttore Tecnico/Scientifico/R&S | 01/07/2014 | - |
Formazione di Irit Gliko-Kabir
The Hebrew University of Jerusalem | Doctorate Degree |
Statistiche
Distribuzione geografica
Israele | 4 |
Posizioni
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 1 |
Graduate Degree | 1 |
Settori
Health Technology | 3 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
BIOLINERX LTD. | Health Technology |
Aziende private | 1 |
---|---|
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Health Technology |
- Borsa valori
- Insiders
- Irit Gliko-Kabir
- Esperienza